Adaptive Biotechnologies Corp vs SAP SE — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while SAP SE trades at $207.06 (market cap $240.81B). The key difference: SAP SE is far larger — about 59.6× Adaptive Biotechnologies Corp's market cap, and SAP SE pays a 1.4% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SAP | |
|---|---|---|
Market Cap | $4.04B | $240.81B |
Sector | Health | Technology |
52-Week High | $25.45 | $280.46 |
52-Week Low | $12.30 | $146.38 |
Enterprise Value | $4.10B | $239.52B |
Dividend Yield | — | 1.4% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →